

July 22, 2021



LIXTE BIOTECHNOLOGY COMMENTS ON REPORT THAT ITS PP2A INHIBITOR LB-100 COMBINED WITH ANOTHER INVESTIGATIONAL AGENT STIMULATES BONE GROWTH IN MODELS OF DWARFISM

Altadena, CA, July 22, 2021 (GLOBE NEWSWIRE) -- [Lixte Biotechnology Holdings, Inc. \(Nasdaq:LIXTE\)](#) a clinical-stage drug discovery company developing pharmacologically active drugs for improving cancer treatments, commented on pre-clinical research demonstrating that inhibition of protein phosphatase 2A (PP2A) with LB-100 combined with the experimental drug, vosoritide (BioMarin), was even more effective than vosoritide alone in stimulating bone length and cartilage area in a mouse model of the most common form of dwarfism, achondroplasia (ACH).

In clinical trials, the BioMarin compound alone was beneficial. But the fact that the addition of LB-100 enhanced the activity of vosoritide in the animal models of ACH led the authors to conclude that their study provides a proof of concept that a phosphatase inhibitor may be a beneficial addition to therapy with vosoritide ([Shuhaibar et al., JCI Insight 2021](#)).

Lixte CEO, John S. Kovach MD, commented “Our development of LB-100 as the only presently available PP2A inhibitor in clinical trials has opened a multitude of possibilities for adding inhibition of PP2A to therapeutic regimens for a range of serious diseases. LB-100 has been shown to enhance anti-cancer activity of standard chemotherapy and immunotherapy regimens against a broad spectrum of human cancers in animal models. Our focus is to demonstrate the clinical therapeutic benefit of LB-100 in one or more cancers for which more effective treatments are urgently needed. We are concentrating on small cell lung cancer and advanced soft tissue sarcomas. Many investigators of which Shuhaibar and colleagues are among the most recent have used LB-100 in pre-clinical studies that have revealed targeting of PP2A function appears to have a multitude of potential applications to serious human diseases in addition to cancer.”

About Lixte Biotechnology Holdings, Inc.

[Lixte Biotechnology Holdings, Inc. \(Nasdaq:LIXT\)](#) is a clinical-stage pharmaceutical company dedicated to discovering drugs for more effective treatments for many forms of cancer and other serious common diseases. A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off. Most cancer research over the past 30 years has focused on the “on” switches because the “off” switches, especially the master “off” switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients. Lixte has achieved a breakthrough with its novel, first-in-class lead compound, PP2A inhibitor LB-100, by demonstrating that it is readily tolerated in cancer patients at doses associated with anti-cancer activity. This innovative approach encourages cancer cells, damaged by chemotherapy or other cancer therapies, to continue to replicate before repairing the damage, leading to the more efficient death and elimination of those cells from the body. Lixte has partnered with top medical institutions and leading academic research centers to advance the clinical development of its compounds. The LB-100 compound, of which there are no competitors known to Lixte, is being tested in three clinical cancer treatment studies with others in planning. Additional information can be obtained at the Company’s website at www.lixte.com.

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company’s financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as “intend,” “anticipate,” “believe,” “estimate,” “potential(ly),” “continue,” “forecast,” “predict,” “plan,” “may,” “will,” “could,” “would,” “should,” “expect” or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company’s filings with the United States Securities and Exchange Commission at sec.gov/edgar.shtml.

Lixte Contact:

info@lixte.com

General Phone: (631) 830-7092

Investor Phone: (888) 289-5533



Source: Lixte Biotechnology Holdings, Inc.